根据格拉斯哥昏迷量表评分确定小儿脑外伤患者的左乙拉西坦剂量。

IF 1.1 4区 医学 Q4 CLINICAL NEUROLOGY Neuropediatrics Pub Date : 2024-08-01 Epub Date: 2024-05-13 DOI:10.1055/s-0044-1786796
Victoria Miklus, Lindsay Trout, Katelyn Even
{"title":"根据格拉斯哥昏迷量表评分确定小儿脑外伤患者的左乙拉西坦剂量。","authors":"Victoria Miklus, Lindsay Trout, Katelyn Even","doi":"10.1055/s-0044-1786796","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Severe traumatic brain injury (TBI) increases the risk of early posttraumatic seizures (EPTS). Guidelines suggest the use of prophylactic antiseizure agents, including levetiracetam. This study aims to evaluate the feasibility of using levetiracetam dosing based on Glasgow Comas Scale (GCS) scores with higher doses used for more severe TBI.</p><p><strong>Methods: </strong>Patients 6 months to 18 years old admitted to Penn State Hershey Children's Hospital (PSHCH) with a TBI who received levetiracetam for EPTS prophylaxis with at least one documented GCS score were included. Patients were divided into two cohorts: before and after implementation of the pediatric TBI Cerner PowerPlan at PSHCH which standardized levetiracetam dosing based on GCS scores. Primary outcome was appropriate dosing of levetiracetam based on GCS. Secondary outcomes included seizure occurrence and adverse effects.</p><p><strong>Results: </strong>Eighty-five patients were included: 42 in the pre-PowerPlan group and 43 in the post-PowerPlan group. Overall, 46 (54%) patients received the appropriate levetiracetam dose based on GCS (pre-PowerPlan, <i>n</i> = 19 [45%] vs. post-PowerPlan <i>n</i> = 27 [63%], <i>p</i> = 0.104). Sixty-four percent of severe TBI patients received appropriate levetiracetam dosing after implantation of the PowerPlan compared with 28% prior to the PowerPlan (<i>p</i> = 0.039). Three patients in each group experienced a seizure while on levetiracetam. Two patients experienced agitation and somnolence attributed to levetiracetam.</p><p><strong>Conclusion: </strong>Levetiracetam dosing based on GCS scores in pediatric TBI patients is a novel approach, and dosing accuracy may be increased with use of a PowerPlan. Additional large-scale studies are needed to evaluate efficacy and safety of this approach prior to widespread implementation.</p>","PeriodicalId":19421,"journal":{"name":"Neuropediatrics","volume":" ","pages":"224-231"},"PeriodicalIF":1.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Levetiracetam Dosing Based on Glasgow Coma Scale Scores in Pediatric Traumatic Brain Injury Patients.\",\"authors\":\"Victoria Miklus, Lindsay Trout, Katelyn Even\",\"doi\":\"10.1055/s-0044-1786796\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Severe traumatic brain injury (TBI) increases the risk of early posttraumatic seizures (EPTS). Guidelines suggest the use of prophylactic antiseizure agents, including levetiracetam. This study aims to evaluate the feasibility of using levetiracetam dosing based on Glasgow Comas Scale (GCS) scores with higher doses used for more severe TBI.</p><p><strong>Methods: </strong>Patients 6 months to 18 years old admitted to Penn State Hershey Children's Hospital (PSHCH) with a TBI who received levetiracetam for EPTS prophylaxis with at least one documented GCS score were included. Patients were divided into two cohorts: before and after implementation of the pediatric TBI Cerner PowerPlan at PSHCH which standardized levetiracetam dosing based on GCS scores. Primary outcome was appropriate dosing of levetiracetam based on GCS. Secondary outcomes included seizure occurrence and adverse effects.</p><p><strong>Results: </strong>Eighty-five patients were included: 42 in the pre-PowerPlan group and 43 in the post-PowerPlan group. Overall, 46 (54%) patients received the appropriate levetiracetam dose based on GCS (pre-PowerPlan, <i>n</i> = 19 [45%] vs. post-PowerPlan <i>n</i> = 27 [63%], <i>p</i> = 0.104). Sixty-four percent of severe TBI patients received appropriate levetiracetam dosing after implantation of the PowerPlan compared with 28% prior to the PowerPlan (<i>p</i> = 0.039). Three patients in each group experienced a seizure while on levetiracetam. Two patients experienced agitation and somnolence attributed to levetiracetam.</p><p><strong>Conclusion: </strong>Levetiracetam dosing based on GCS scores in pediatric TBI patients is a novel approach, and dosing accuracy may be increased with use of a PowerPlan. Additional large-scale studies are needed to evaluate efficacy and safety of this approach prior to widespread implementation.</p>\",\"PeriodicalId\":19421,\"journal\":{\"name\":\"Neuropediatrics\",\"volume\":\" \",\"pages\":\"224-231\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuropediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0044-1786796\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0044-1786796","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:严重创伤性脑损伤(TBI)会增加早期创伤后癫痫发作(EPTS)的风险。指南建议使用预防性抗癫痫药物,包括左乙拉西坦。本研究旨在评估根据格拉斯哥昏迷量表(GCS)评分使用左乙拉西坦剂量的可行性,并对更严重的创伤性脑损伤使用更大剂量:纳入宾夕法尼亚州立赫尔希儿童医院(PSHCH)收治的 6 个月至 18 岁的 TBI 患者,这些患者曾接受左乙拉西坦治疗以预防 EPTS,且至少有一次 GCS 评分记录。患者被分为两组:在 PSHCH 实施儿科 TBI Cerner PowerPlan 之前和之后,该计划根据 GCS 评分对左乙拉西坦剂量进行了标准化。主要结果是根据 GCS 评分确定左乙拉西坦的适当剂量。次要结果包括癫痫发作和不良反应:共纳入 85 名患者:结果:共纳入 85 名患者:42 名属于 "PowerPlan "前治疗组,43 名属于 "PowerPlan "后治疗组。总体而言,46 名(54%)患者根据 GCS 获得了适当的左乙拉西坦剂量(PowerPlan 前 n = 19 [45%] vs. Post-PowerPlan 后 n = 27 [63%],p = 0.104)。植入 PowerPlan 后,64% 的严重 TBI 患者获得了适当的左乙拉西坦剂量,而植入 PowerPlan 前仅为 28%(p = 0.039)。每组中都有三名患者在服用左乙拉西坦期间出现癫痫发作。两名患者因服用左乙拉西坦而出现躁动和嗜睡:根据儿童 TBI 患者的 GCS 评分确定左乙拉西坦剂量是一种新方法,使用 PowerPlan 可提高剂量的准确性。在广泛实施之前,还需要进行更多的大规模研究,以评估这种方法的疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Levetiracetam Dosing Based on Glasgow Coma Scale Scores in Pediatric Traumatic Brain Injury Patients.

Introduction: Severe traumatic brain injury (TBI) increases the risk of early posttraumatic seizures (EPTS). Guidelines suggest the use of prophylactic antiseizure agents, including levetiracetam. This study aims to evaluate the feasibility of using levetiracetam dosing based on Glasgow Comas Scale (GCS) scores with higher doses used for more severe TBI.

Methods: Patients 6 months to 18 years old admitted to Penn State Hershey Children's Hospital (PSHCH) with a TBI who received levetiracetam for EPTS prophylaxis with at least one documented GCS score were included. Patients were divided into two cohorts: before and after implementation of the pediatric TBI Cerner PowerPlan at PSHCH which standardized levetiracetam dosing based on GCS scores. Primary outcome was appropriate dosing of levetiracetam based on GCS. Secondary outcomes included seizure occurrence and adverse effects.

Results: Eighty-five patients were included: 42 in the pre-PowerPlan group and 43 in the post-PowerPlan group. Overall, 46 (54%) patients received the appropriate levetiracetam dose based on GCS (pre-PowerPlan, n = 19 [45%] vs. post-PowerPlan n = 27 [63%], p = 0.104). Sixty-four percent of severe TBI patients received appropriate levetiracetam dosing after implantation of the PowerPlan compared with 28% prior to the PowerPlan (p = 0.039). Three patients in each group experienced a seizure while on levetiracetam. Two patients experienced agitation and somnolence attributed to levetiracetam.

Conclusion: Levetiracetam dosing based on GCS scores in pediatric TBI patients is a novel approach, and dosing accuracy may be increased with use of a PowerPlan. Additional large-scale studies are needed to evaluate efficacy and safety of this approach prior to widespread implementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuropediatrics
Neuropediatrics 医学-临床神经学
CiteScore
2.80
自引率
0.00%
发文量
94
审稿时长
>12 weeks
期刊介绍: For key insights into today''s practice of pediatric neurology, Neuropediatrics is the worldwide journal of choice. Original articles, case reports and panel discussions are the distinctive features of a journal that always keeps abreast of current developments and trends - the reason it has developed into an internationally recognized forum for specialists throughout the world. Pediatricians, neurologists, neurosurgeons, and neurobiologists will find it essential reading.
期刊最新文献
Precision Medicine in Angelman Syndrome. Amplitude-Integrated Electroencephalogram in Premature Infants: A Prospective Cohort Study. Diagnostic Approach to Children with Unexplained Global Developmental Delay in Pediatric Neurology Outpatient Clinic. Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders. Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1